中藥板塊走強 多地出台中醫藥“加強版”規劃
格隆匯4月21日丨中藥板塊大幅走強,方盛製藥、金陵藥業、西藏藥業、特一藥業漲停,吉藥控股漲超7%,奇正藏藥、葫蘆娃、嘉應制藥、葵花葯業等紛紛衝高。近日,北京下發《關於促進中醫藥傳承創新發展的實施方案》,堅持中西醫並重,推動中醫藥和西醫藥相互補充、協調發展,推動中醫藥事業和產業高質量發展。在此之前,上海市人大常委會表決通過《上海市中醫藥條例》指出,加強中醫藥服務體系建設,提供覆蓋全民和全生命週期的中醫藥服務。業內人士表示,隨着多地中醫藥發展迎來“加強版”規劃,中醫藥企業創新研發也不斷深入,中醫藥行業進入黃金髮展新階段。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.